RedHill Biopharma Ltd – (NASDAQ:RDHL) traded down 4.2% on Monday . The company traded as low as $15.19 and last traded at $15.39, with a volume of 59,290 shares changing hands. The stock had previously closed at $16.07.

A number of equities research analysts have weighed in on the stock. FBR & Co reissued a “buy” rating on shares of RedHill Biopharma Ltd – in a report on Tuesday, May 3rd. Zacks Investment Research downgraded shares of RedHill Biopharma Ltd – from a “buy” rating to a “hold” rating in a report on Wednesday, July 6th. Two investment analysts have rated the stock with a sell rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $26.00.

The stock’s market capitalization is $195.34 million. The company’s 50 day moving average price is $11.90 and its 200-day moving average price is $11.26.

RedHill Biopharma Ltd – (NASDAQ:RDHL) last released its quarterly earnings data on Wednesday, July 27th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.52. On average, equities research analysts predict that RedHill Biopharma Ltd – will post ($2.06) EPS for the current fiscal year.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.